AT THE iQ GROUP GLOBAL,

That’s all we think about

We are a consortium of companies who work together to find, fund and develop bioscience discoveries into life-changing medical innovations – and take them to the people who need them most.

Our scientific team identifies scientific discoveries from laboratories all over the world that have the potential to have life-changing impact.
Our corporate advisory and investment banking teams work together to translate scientific milestones into value creation events, creating financial instruments and corporate structures that activate commercial value.
Our commercialization team partners with healthcare providers and unlocks regulatory pathways to take the discovery to the people who need it.

The story so far

2019

The iQ Group Global acquires TEX Core, an anti-cancer drug platform
Recognised as one of Australia and New Zealand’s Top 5 Most Innovative Companies by The Australian Financial Review and BOSS Magazine
FarmaForce wins Sales Team of the Year at PRIME Awards for the third time

2018

China patent granted for Saliva Glucose Biosensor
FarmaForce wins Sales Team of the Year at PRIME Awards for the second time

2017

US patent granted for Saliva Glucose Biosensor

2016

The iQ Group Global accelerated the development of the Saliva Glucose Biosensor
iQ Capital incorporated in the USA
Series 8 Fund launched
FarmaForce wins Sales Team of the Year at PRIME Awards

2015

iQ3 ASX listed
FarmaForce ASX listed

2014

Inception of CRC and FarmaForce

2013

iQX lists on NSX
iQ3 inception
OTFT-based saliva glucose biosensor invented by Professor Dastoor and team. IP filed in March

2012

iQnovate commences trading in the USA

2011

iQnovate lists on NSX
iQX inception

2010

Inception of iQnovate

Our Partners

Meet the people bringing our technology to life